Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
2.
J Cachexia Sarcopenia Muscle ; 12(3): 677-693, 2021 06.
Article in English | MEDLINE | ID: mdl-34037326

ABSTRACT

BACKGROUND: Duchenne muscular dystrophy (DMD) is a lethal muscle disease detected in approximately 1:5000 male births. DMD is caused by mutations in the DMD gene, encoding a critical protein that links the cytoskeleton and the extracellular matrix in skeletal and cardiac muscles. The primary consequence of the disrupted link between the extracellular matrix and the myofibre actin cytoskeleton is thought to involve sarcolemma destabilization, perturbation of Ca2+ homeostasis, activation of proteases, mitochondrial damage, and tissue degeneration. A recently emphasized secondary aspect of the dystrophic process is a progressive metabolic change of the dystrophic tissue; however, the mechanism and nature of the metabolic dysregulation are yet poorly understood. In this study, we characterized a molecular mechanism of metabolic perturbation in DMD. METHODS: We sequenced plasma miRNA in a DMD cohort, comprising 54 DMD patients treated or not by glucocorticoid, compared with 27 healthy controls, in three groups of the ages of 4-8, 8-12, and 12-20 years. We developed an original approach for the biological interpretation of miRNA dysregulation and produced a novel hypothesis concerning metabolic perturbation in DMD. We used the mdx mouse model for DMD for the investigation of this hypothesis. RESULTS: We identified 96 dysregulated miRNAs (adjusted P-value <0.1), of which 74 were up-regulated and 22 were down-regulated in DMD. We confirmed the dysregulation in DMD of Dystro-miRs, Cardio-miRs, and a large number of the DLK1-DIO3 miRNAs. We also identified numerous dysregulated miRNAs yet unreported in DMD. Bioinformatics analysis of both target and host genes for dysregulated miRNAs predicted that lipid metabolism might be a critical metabolic perturbation in DMD. Investigation of skeletal muscles of the mdx mouse uncovered dysregulation of transcription factors of cholesterol and fatty acid metabolism (SREBP-1 and SREBP-2), perturbation of the mevalonate pathway, and the accumulation of cholesterol in the dystrophic muscles. Elevated cholesterol level was also found in muscle biopsies of DMD patients. Treatment of mdx mice with Simvastatin, a cholesterol-reducing agent, normalized these perturbations and partially restored the dystrophic parameters. CONCLUSIONS: This investigation supports that cholesterol metabolism and the mevalonate pathway are potential therapeutic targets in DMD.


Subject(s)
Muscular Dystrophy, Duchenne , Animals , Cholesterol/metabolism , Humans , Lipid Metabolism , Male , Mice , Mice, Inbred mdx , Muscle, Skeletal/metabolism , Muscular Dystrophy, Duchenne/genetics
3.
Sci Transl Med ; 11(520)2019 11 27.
Article in English | MEDLINE | ID: mdl-31776291

ABSTRACT

Limb-girdle muscular dystrophy type 2A (LGMD2A or LGMDR1) is a neuromuscular disorder caused by mutations in the calpain 3 gene (CAPN3). Previous experiments using adeno-associated viral (AAV) vector-mediated calpain 3 gene transfer in mice indicated cardiac toxicity associated with the ectopic expression of the calpain 3 transgene. Here, we performed a preliminary dose study in a severe double-knockout mouse model deficient in calpain 3 and dysferlin. We evaluated safety and biodistribution of AAV9-desmin-hCAPN3 vector administration to nonhuman primates (NHPs) with a dose of 3 × 1013 viral genomes/kg. Vector administration did not lead to observable adverse effects or to detectable toxicity in NHP. Of note, the transgene expression did not produce any abnormal changes in cardiac morphology or function of injected animals while reaching therapeutic expression in skeletal muscle. Additional investigation on the underlying causes of cardiac toxicity observed after gene transfer in mice and the role of titin in this phenomenon suggest species-specific titin splicing. Mice have a reduced capacity for buffering calpain 3 activity compared to NHPs and humans. Our studies highlight a complex interplay between calpain 3 and titin binding sites and demonstrate an effective and safe profile for systemic calpain 3 vector delivery in NHP, providing critical support for the clinical potential of calpain 3 gene therapy in humans.


Subject(s)
Calpain/genetics , Calpain/therapeutic use , Cardiotoxicity/etiology , Connectin/genetics , Genetic Therapy/adverse effects , Muscle Proteins/genetics , Muscle Proteins/therapeutic use , Muscular Dystrophies, Limb-Girdle/genetics , Muscular Dystrophies, Limb-Girdle/therapy , RNA Splicing/genetics , Animals , Binding Sites , Biomarkers/blood , Cardiotoxicity/blood , Connectin/chemistry , Dependovirus/genetics , Dysferlin/deficiency , Dysferlin/metabolism , Enzyme Stability , Gene Expression Regulation , Mice, Knockout , MicroRNAs/genetics , MicroRNAs/metabolism , Muscle, Skeletal/metabolism , Muscular Dystrophies, Limb-Girdle/blood , Muscular Dystrophies, Limb-Girdle/pathology , Myocardium/metabolism , Myocardium/pathology , Primates , Protein Domains , Proteolysis , Species Specificity , Tissue Distribution , Transgenes
4.
Hum Mol Genet ; 25(20): 4518-4532, 2016 10 15.
Article in English | MEDLINE | ID: mdl-28173117

ABSTRACT

The giant protein titin is the third most abundant protein in striated muscle. Mutations in its gene are responsible for diseases affecting the cardiac and/or the skeletal muscle. Titin has been reported to be expressed in multiple isoforms with considerable variability in the I-band, ensuring the modulation of the passive mechanical properties of the sarcomere. In the M-line, only the penultimate Mex5 exon coding for the specific is7 domain has been reported to be subjected to alternative splicing. Using the CRISPR-Cas9 editing technology, we generated a mouse model where we stably prevent the expression of alternative spliced variant(s) carrying the corresponding domain. Interestingly, the suppression of the domain induces a phenotype mostly in tissues usually expressing the isoform that has been suppressed, indicating that it fulfills (a) specific function(s) in these tissues allowing a perfect adaptation of the M-line to physiological demands of different muscles.


Subject(s)
Alternative Splicing , CRISPR-Cas Systems , Gene Editing/methods , Models, Animal , Protein Kinases/metabolism , Animals , Male , Mice , Protein Isoforms/genetics , Protein Kinases/genetics , Sarcomeres/metabolism
5.
Hum Mol Genet ; 24(13): 3718-31, 2015 Jul 01.
Article in English | MEDLINE | ID: mdl-25877298

ABSTRACT

Mutations in the extreme C-terminus of titin (TTN), situated in the sarcomeric M-band, cause tibial muscular dystrophy (TMD) and limb-girdle muscular dystrophy 2J (LGMD2J). The mutations ultimately cause a loss of C-terminal titin, including a binding site for the protease calpain 3 (CAPN3), and lead to a secondary CAPN3 deficiency in LGMD2J muscle. CAPN3 has been previously shown to bind C-terminal titin and to use it as a substrate in vitro. Interestingly, mutations in CAPN3 underlie limb-girdle muscular dystrophy 2A (LGMD2A). Here, we aimed to clarify the relationship of CAPN3 and M-band titin in normal and pathological muscle. In vitro analyses identified several CAPN3 cleavage sites in C-terminal titin that were defined by protein sequencing. Furthermore, cleavage products were detected in normal muscle extracts by western blotting and in situ by immunofluorescence microscopy. The TMD/LGMD2J mutation FINmaj proved to alter this processing in vitro, while binding of CAPN3 to mutant titin was preserved. Unexpectedly, the pathological loss of M-band titin due to TMD/LGMD2J mutations was found to be independent of CAPN3, whereas the involvement of ubiquitous calpains is likely. We conclude that proteolytic processing of C-terminal titin by CAPN3 may have an important role in normal muscle, and that this process is disrupted in LGMD2A and in TMD/LGMD2J due to CAPN3 deficiency and to the loss of C-terminal titin, respectively.


Subject(s)
Calpain/metabolism , Connectin/chemistry , Connectin/metabolism , Distal Myopathies/metabolism , Muscle Proteins/metabolism , Muscular Dystrophies, Limb-Girdle/enzymology , Protein Kinases/chemistry , Protein Kinases/metabolism , Amino Acid Motifs , Animals , Calpain/genetics , Connectin/genetics , Distal Myopathies/genetics , Female , Humans , Male , Mice , Mice, Inbred C57BL , Muscle Proteins/genetics , Muscle, Skeletal/enzymology , Muscle, Skeletal/metabolism , Muscular Dystrophies, Limb-Girdle/genetics , Protein Binding , Protein Kinases/genetics , Protein Processing, Post-Translational , Proteolysis
6.
Mol Ther ; 22(6): 1176-1187, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24618805

ABSTRACT

Muscular dystrophies are a group of genetically distinct diseases for which no treatment exists. While gene transfer approach is being tested for several of these diseases, such strategies can be hampered when the size of the corresponding complementary DNA (cDNA) exceeds the packaging capacity of adeno-associated virus vectors. This issue concerns, in particular, dysferlinopathies and titinopathies that are due to mutations in the dysferlin (DYSF) and titin (TTN) genes. We investigated the efficacy of RNA trans-splicing as a mode of RNA therapy for these two types of diseases. Results obtained with RNA trans-splicing molecules designed to target the 3' end of mouse titin and human dysferlin pre-mRNA transcripts indicated that trans-splicing of pre-mRNA generated from minigene constructs or from the endogenous genes was achieved. Collectively, these results provide the first demonstration of DYSF and TTN trans-splicing reprogramming in vitro and in vivo. However, in addition to these positive results, we uncovered a possible issue of the technique in the form of undesirable translation of RNA pre-trans-splicing molecules, directly from open reading frames present on the molecule or associated with internal alternative cis-splicing. These events may hamper the efficiency of the trans-splicing process and/or lead to toxicity.


Subject(s)
Membrane Proteins/genetics , Membrane Proteins/metabolism , Muscular Dystrophies/therapy , Protein Kinases/genetics , Protein Kinases/metabolism , RNA Precursors/genetics , RNA, Messenger/metabolism , Alternative Splicing , Animals , Cell Line , Dysferlin , Humans , Mice , Mice, Inbred C57BL , Molecular Targeted Therapy , Muscular Dystrophies/genetics , Open Reading Frames , Trans-Splicing
7.
Circulation ; 128(10): 1094-104, 2013 Sep 03.
Article in English | MEDLINE | ID: mdl-23908349

ABSTRACT

BACKGROUND: Genetic defects in calpain3 (CAPN3) lead to limb-girdle muscular dystrophy type 2A, a disease of the skeletal muscle that affects predominantly the proximal limb muscles. We previously demonstrated the potential of adeno-associated virus-mediated transfer of the CAPN3 gene to correct the pathological signs in a murine model for limb-girdle muscular dystrophy type 2A after intramuscular and locoregional administrations. METHODS AND RESULTS: Here, we showed that intravenous injection of calpain3-expressing vector in mice can induce mortality in a dose-dependent manner. An anatomopathological investigation revealed large areas of fibrosis in the heart that we related to unregulated proteolytic activity of calpain3. To circumvent this toxicity, we developed new adeno-associated virus vectors with skeletal muscle-restricted expression by using new muscle-specific promoters that include the CAPN3 promoter itself and by introducing a target sequence of the cardiac-specific microRNA-208a in the cassette. Our results show that CAPN3 transgene expression can be successfully suppressed in the cardiac tissue, preventing the cardiac toxicity, whereas expression of the transgene in skeletal muscle reverts the pathological signs of calpain3 deficiency. CONCLUSIONS: The molecular strategies used in this study may be useful for any gene transfer strategy with potential toxicity in the heart.


Subject(s)
Calpain/antagonists & inhibitors , Gene Expression Regulation, Enzymologic , Muscle Proteins/antagonists & inhibitors , Muscle, Skeletal/enzymology , Muscle, Skeletal/pathology , Muscular Dystrophies, Limb-Girdle/enzymology , Muscular Dystrophies, Limb-Girdle/pathology , Animals , Calpain/biosynthesis , Calpain/genetics , Gene Expression Regulation, Enzymologic/physiology , Genetic Vectors/administration & dosage , Genetic Vectors/genetics , HEK293 Cells , HeLa Cells , Human Umbilical Vein Endothelial Cells , Humans , Mice , Mice, Inbred C57BL , Mice, Knockout , Muscle Proteins/biosynthesis , Muscle Proteins/genetics , Muscular Dystrophies, Limb-Girdle/genetics
8.
PLoS One ; 7(5): e38036, 2012.
Article in English | MEDLINE | ID: mdl-22666441

ABSTRACT

Mutations in the dysferlin gene are the cause of Limb-girdle Muscular Dystrophy type 2B and Miyoshi Myopathy. The dysferlin protein has been implicated in sarcolemmal resealing, leading to the idea that the pathophysiology of dysferlin deficiencies is due to a deficit in membrane repair. Here, we show using two different approaches that fulfilling membrane repair as asseyed by laser wounding assay is not sufficient for alleviating the dysferlin deficient pathology. First, we generated a transgenic mouse overexpressing myoferlin to test the hypothesis that myoferlin, which is homologous to dysferlin, can compensate for the absence of dysferlin. The myoferlin overexpressors show no skeletal muscle abnormalities, and crossing them with a dysferlin-deficient model rescues the membrane fusion defect present in dysferlin-deficient mice in vitro. However, myoferlin overexpression does not correct muscle histology in vivo. Second, we report that AAV-mediated transfer of a minidysferlin, previously shown to correct the membrane repair deficit in vitro, also fails to improve muscle histology. Furthermore, neither myoferlin nor the minidysferlin prevented myofiber degeneration following eccentric exercise. Our data suggest that the pathogenicity of dysferlin deficiency is not solely related to impairment in sarcolemmal repair and highlight the care needed in selecting assays to assess potential therapies for dysferlinopathies.


Subject(s)
Cell Membrane/metabolism , Cell Membrane/pathology , Genetic Therapy/methods , Muscular Dystrophies, Limb-Girdle/genetics , Muscular Dystrophies, Limb-Girdle/pathology , Animals , Bystander Effect/genetics , Dependovirus/genetics , Dysferlin , Female , Gene Deletion , Gene Expression Regulation/genetics , Humans , Male , Membrane Fusion/genetics , Membrane Proteins/deficiency , Membrane Proteins/genetics , Mice , Mice, Transgenic , Muscle Proteins/genetics , Muscles/metabolism , Muscles/pathology , Muscles/physiopathology , Muscular Dystrophies, Limb-Girdle/therapy , Phenotype , Sarcolemma/metabolism , Sarcolemma/pathology , Treatment Outcome
9.
FEBS J ; 277(20): 4322-37, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20860623

ABSTRACT

A multiprotein complex encompassing a transcription regulator, cardiac ankyrin repeat protein (CARP), and the calpain 3 protease was identified in the N2A elastic region of the giant sarcomeric protein titin. The present study aimed to investigate the function(s) of this complex in the skeletal muscle. We demonstrate that CARP subcellular localization is controlled by the activity of calpain 3: the higher the calpain 3, the more important the sarcomeric retention of CARP. This regulation would occur through cleavage of the N-terminal end of CARP by the protease. We show that, upon CARP over-expression, the transcription factor nuclear factor NF-κB p65 DNA-binding activity decreases. Taken as a whole, CARP and its regulator calpain 3 appear to occupy a central position in the important cell fate-governing NF-κB pathway. Interestingly, the expression of the atrophying protein MURF1, one of NF-κB main targets, remains unchanged in presence of CARP, suggesting that the pathway encompassing calpain 3/CARP/NF-κB does not play a role in muscle atrophy. With NF-κB also having anti-apoptotic effects, the inability of calpain 3 to lower CARP-driven inhibition of NF-κB could reduce muscle cell survival, hence partly accounting for the dystrophic pattern observed in limb girdle muscular dystrophy 2A, a pathology resulting from the protease deficiency.


Subject(s)
Calpain/metabolism , Muscle Proteins/metabolism , Muscle, Skeletal/metabolism , NF-kappa B/metabolism , Nuclear Proteins/metabolism , Repressor Proteins/metabolism , Signal Transduction/physiology , Humans , Muscular Dystrophies, Limb-Girdle/pathology , NF-kappa B/antagonists & inhibitors
10.
FEBS J ; 276(3): 669-84, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19143834

ABSTRACT

In an attempt to identify potential therapeutic targets for the correction of muscle wasting, the gene expression of several pivotal proteins involved in protein metabolism was investigated in experimental atrophy induced by transient or definitive denervation, as well as in four animal models of muscular dystrophies (deficient for calpain 3, dysferlin, alpha-sarcoglycan and dystrophin, respectively). The results showed that: (a) the components of the ubiquitin-proteasome pathway are upregulated during the very early phases of atrophy but do not greatly increase in the muscular dystrophy models; (b) forkhead box protein O1 mRNA expression is augmented in the muscles of a limb girdle muscular dystrophy 2A murine model; and (c) the expression of cardiac ankyrin repeat protein (CARP), a regulator of transcription factors, appears to be persistently upregulated in every condition, suggesting that CARP could be a hub protein participating in common pathological molecular pathway(s). Interestingly, the mRNA level of a cell cycle inhibitor known to be upregulated by CARP in other tissues, p21(WAF1/CIP1), is consistently increased whenever CARP is upregulated. CARP overexpression in muscle fibres fails to affect their calibre, indicating that CARP per se cannot initiate atrophy. However, a switch towards fast-twitch fibres is observed, suggesting that CARP plays a role in skeletal muscle plasticity. The observation that p21(WAF1/CIP1) is upregulated, put in perspective with the effects of CARP on the fibre type, fits well with the idea that the mechanisms at stake might be required to oppose muscle remodelling in skeletal muscle.


Subject(s)
Muscle, Skeletal/metabolism , Muscular Atrophy/metabolism , Muscular Atrophy/pathology , Muscular Dystrophies/metabolism , Muscular Dystrophies/pathology , Nuclear Proteins/metabolism , Repressor Proteins/metabolism , Animals , Biomarkers/metabolism , Calpain/deficiency , Calpain/genetics , Calpain/metabolism , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Disease Models, Animal , Forkhead Box Protein O1 , Forkhead Transcription Factors/metabolism , Gene Expression Profiling , Male , Mice , Muscle Proteins/deficiency , Muscle Proteins/genetics , Muscle Proteins/metabolism , Muscular Atrophy/genetics , Muscular Dystrophies/genetics , Nuclear Proteins/genetics , Proteasome Endopeptidase Complex/metabolism , Repressor Proteins/genetics , Signal Transduction , Up-Regulation
11.
FASEB J ; 22(5): 1521-9, 2008 May.
Article in English | MEDLINE | ID: mdl-18073330

ABSTRACT

Limb-girdle muscular dystrophy type 2A (LGMD2A) is a recessive genetic disorder caused by mutations in the cysteine protease calpain 3 (CAPN3) that leads to selective muscle wasting. We previously showed that CAPN3 deficiency is associated with a profound perturbation of the NF-kappaB/IkappaB alpha survival pathway. In this study, the consequences of altered NF-kappaB/IkappaB alpha pathway were investigated using biological materials from LGMD2A patients. We first show that the antiapoptotic factor cellular-FLICE inhibitory protein (c-FLIP), which is dependent on the NF-kappaB pathway in normal muscle cells, is down-regulated in LGMD2A biopsies. In muscle cells isolated from LGMD2A patients, NF-kappaB is readily activated on cytokine induction as shown by an increase in its DNA binding activity. However, we observed discrepant transcriptional responses depending on the NF-kappaB target genes. IkappaB alpha is expressed following NF-kappaB activation independent of the CAPN3 status, whereas expression of c-FLIP is obtained only when CAPN3 is present. These data lead us to postulate that CAPN3 intervenes in the regulation of the expression of NF-kappaB-dependent survival genes to prevent apoptosis in skeletal muscle. Deregulations in the NF-kappaB pathway could be part of the mechanism responsible for the muscle wasting resulting from CAPN3 deficiency.


Subject(s)
CASP8 and FADD-Like Apoptosis Regulating Protein/biosynthesis , Calpain/physiology , Muscle Proteins/physiology , Muscular Dystrophies, Limb-Girdle/physiopathology , NF-kappa B/physiology , Apoptosis/physiology , Calpain/deficiency , Cells, Cultured , Down-Regulation , Humans , I-kappa B Proteins/biosynthesis , Interleukin-1beta/physiology , Models, Biological , Muscle Proteins/deficiency , Muscle, Skeletal/metabolism , Tumor Necrosis Factor-alpha/physiology , bcl-2-Associated X Protein/biosynthesis , bcl-X Protein/biosynthesis
12.
Mol Ther ; 13(2): 250-9, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16290124

ABSTRACT

Calpainopathy (limb-girdle muscular dystrophy type 2A, LGMD2A) is a recessive muscular disorder caused by deficiency in the calcium-dependent cysteine protease calpain 3. To date, no treatment exists for this disease. We evaluated the potential of recombinant adeno-associated virus (rAAV) vectors for gene therapy in a murine model for LGMD2A. To drive the expression of calpain 3, we used rAAV2/1 pseudotyped vectors and muscle-specific promoters to avoid calpain 3 cell toxicity. We report efficient and stable transgene expression in muscle with restoration of the proteolytic activity and without evident toxicity. In addition, calpain 3 was correctly targeted to the sarcomere. Moreover, its presence resulted in improvement of the histological features and in therapeutic efficacy at the physiological levels, including correction of atrophy and full rescue of the contractile force deficits. Our results establish the feasibility of AAV-mediated calpain 3 gene transfer as a therapeutic approach.


Subject(s)
Calpain/genetics , Calpain/therapeutic use , Dependovirus/genetics , Gene Transfer Techniques , Genetic Therapy/methods , Muscle Proteins/genetics , Muscle Proteins/therapeutic use , Muscular Dystrophies, Limb-Girdle/therapy , Animals , Calpain/biosynthesis , Calpain/deficiency , Disease Models, Animal , Enzyme Activation/genetics , Enzyme Stability/genetics , Genetic Vectors/therapeutic use , Injections, Intramuscular , Mice , Mice, Inbred C57BL , Mice, Transgenic , Muscle Proteins/biosynthesis , Muscle Proteins/deficiency , Muscle, Skeletal/enzymology , Muscular Dystrophies, Limb-Girdle/metabolism
13.
J Muscle Res Cell Motil ; 23(3): 255-64, 2002.
Article in English | MEDLINE | ID: mdl-12500905

ABSTRACT

This report describes the characterisation of the expression profile of several myogenic determination genes during human embryogenesis. The data were obtained from axial structures and limb buds of human embryos aged between 3 and 8 weeks of development. Using in situ hybridisation to detect Pax3 and MyoD gene family mRNAs, and immunochemistry to follow Six and Eya protein accumulation, we have been able to establish the chronology of accumulation of these gene products. As in mouse, the first transcripts detected in myotomes of 3 week-old embryos are Pax3 and Myf5, followed by the expression of myogenin. MyoD appears to be activated well after Myf5, myogenin and MRF4 in the early myotome, whereas, in limb bud muscles, the presence of all four of these mRNAs is concomitant from 6 weeks. Six1, Six4 and Six5 homeoproteins are detected later than Myf5 activation. These Six homeoproteins are first observed in the cytoplasm of myogenin expressing cells. At later stages of development, Six1 and Six5, but not Six4, are translocated into the nuclei of myogenic cells, concomitantly with MyHCemb expression. Eya1 and Eya2 proteins, potential Six cofactors, were also detected in myogenin positive cells, but their accumulation was delayed and was mainly cytoplasmic. These results preclude that early activation of Myf5, myogenin and MRF4 is under the control of Six and Eya proteins, while Six and Eya proteins would be involved in later steps of myogenic differentiation.


Subject(s)
Cell Differentiation/genetics , Gene Expression Regulation, Developmental/genetics , Homeodomain Proteins/metabolism , Muscle, Skeletal/embryology , MyoD Protein/genetics , Somites/metabolism , Trans-Activators/metabolism , Transcription Factors , Body Patterning/genetics , Cell Nucleus/genetics , Cell Nucleus/metabolism , Cytoplasm/genetics , Cytoplasm/metabolism , DNA-Binding Proteins/genetics , Humans , Immunohistochemistry , Intracellular Signaling Peptides and Proteins , Muscle Proteins/genetics , Muscle, Skeletal/cytology , Muscle, Skeletal/metabolism , Myogenic Regulatory Factor 5 , Myogenic Regulatory Factors/genetics , Myogenin/genetics , Nuclear Proteins , PAX3 Transcription Factor , Paired Box Transcription Factors , Protein Isoforms/genetics , Protein Isoforms/metabolism , Protein Transport/genetics , Protein Tyrosine Phosphatases , RNA, Messenger/metabolism , Somites/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...